BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed cell death protein 1 modulatorsB-cell maturation protein modulators
TargetsProgrammed cell death protein 1B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPeople'S Liberation Army General Hospital Military Service
China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A